Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials
Abstract Neurodegenerative disease is increasingly prevalent and remains without disease-modifying therapies. Engaging the right target, at the right disease stage, could be an important determinant of success. We annotated targets and eligibility criteria for 3238 neurodegenerative disease trials r...
Main Authors: | Meredith A. Mortberg, Sonia M. Vallabh, Eric Vallabh Minikel |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-21820-1 |
Similar Items
-
Analysis of non-human primate models for evaluating prion disease therapeutic efficacy.
by: Meredith A Mortberg, et al.
Published: (2022-08-01) -
Street typology and bicyclist safety : a systems approach
by: Minikel, Eric Vallabh
Published: (2011) -
Therapeutic Potential of Natural Compounds in Neurodegenerative Diseases: Insights from Clinical Trials
by: Stéphanie Andrade, et al.
Published: (2023-01-01) -
Alzheimer’s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology
by: Mugdha Agarwal, et al.
Published: (2020-12-01) -
Gangliosides as Therapeutic Targets for Neurodegenerative Diseases
by: Orhan Kerim Inci, et al.
Published: (2024-01-01)